by Adam Lingle | Nov 29, 2021 | Clinical Trials
Phase 3 study investigating the efficacy and safety of roxadustat for treatment of anemia in patients with lower risk Myelodysplastic Syndrome (MDS) and low Red Blood Cell (RBC) transfusion burden.
by CharTeam1 | Jun 22, 2021 | Clinical Trials
The KEYNOTE B36 study is a Phase 2 pilot, single-arm, open-label study designed to evaluate the safety and effectiveness of Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T. Study patients use the device concomitant with pembrolizumab for...
by CharTeam1 | Apr 23, 2021 | Clinical Trials
Disease registry encompassing the care of patients with multiple myeloma on panobinostat. Participants will describe current treatment patterns and characterize adverse events in the first or later lines of therapy. Outcomes reported in RECOMM Registry
by CharTeam1 | Apr 23, 2021 | Clinical Trials
Phase 3 study comparing niraparib plus pembrolizumab versus placebo plus pembrolizumab as maintenance therapy for patients that have remained stable or responded to first line platinum based chemo plus pembrolizumab for stage IIIB or IV non-small cell lung cancer...
by CharTeam1 | Apr 23, 2021 | Clinical Trials
A survivorship edpidemiology study describing the long-term real-world use and effectiveness of cemiplimab for cutaneous squamous cell carcinoma (CSCC).
by CharTeam1 | Apr 23, 2021 | Clinical Trials
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard-of-care therapies for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure.
